welcome
therapeutics to improve cardiovascular health
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA approved product and is available in the United States by prescription. For more information about Vascepa visit www.vascepa.com.
recent news
12 Apr 2018
Amarin Sponsors Three Scientific Presentations Scheduled for National Lipid Association Scientific Sessions MORE
12 Apr 2018
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin-Treated Patients with Reduced Kidney Function and Persistent High Triglycerides MORE
Stock Information
- Symbol:
- AMRN (NASDAQ)
- Quote:
- 3.03
- Change:
- -0.06
- Date:
- 4:00 PM ET on Apr 13, 2018
Join Our Mailing List
You may automatically receive Amarin Corporation plc financial information by email.